Загрузка...
Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
A growing body of evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be a powerful option to improve the cardiovascular (CV) prognosis in high CV-risk patients with type 2 diabetes. Despite a significant reduction in major adverse CV events with SGLT2 inhibitor treatm...
Сохранить в:
| Опубликовано в: : | Cardiovasc Diabetol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5639481/ https://ncbi.nlm.nih.gov/pubmed/29025400 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0611-x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|